Compare Natera Inc. Common Stock (NTRA) vs Semtech Corporation Common Stock (SMTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Semtech Corporation Common Stock — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Semtech Corporation Common Stock trades at $155.77 (market cap $16.12B). The key difference: Natera Inc. Common Stock is far larger — about 3.5× Semtech Corporation Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Semtech Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Semtech Corporation Common Stock for 2 Days on average.
| NTRA | SMTC | |
|---|---|---|
Market Cap | $57.03B | $16.12B |
Volume | 1,131,157 | 3,682,647 |
Sector | Health | Technology |
52-Week High | $425.64 | $197.20 |
52-Week Low | $179.42 | $62.57 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $56.18B | $16.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SMTC trades at $172.78, up 2.67% today, with a bullish technical setup near its pivot point of $173. The stock has gained 154% year-to-date, driven by strong AI data center demand and recent earnings beats. Revenue is projected to grow from $909 million in 2025 to $1.2 billion in 2026, with net income turning positive. Analysts maintain a strong buy consensus with an average price target of $216.38.
Outlook is positive given robust AI-driven growth and expanding partnerships, but high valuation multiples and recent insider selling pose risks. The stock's momentum hinges on continued execution in data center markets and the upcoming Q3 2026 earnings report.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Semtech Corporation Common Stock
Semtech develops analog and mixed-signal semiconductors and connectivity products. Its technologies are used in communications, data centers, industrial systems, and IoT devices.
Read more on SMTC →
